KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Equity Ratio (2018 - 2026)

Castle Biosciences' Equity Ratio history spans 8 years, with the latest figure at 0.81 for Q4 2025.

  • On a quarterly basis, Equity Ratio fell 5.15% to 0.81 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.81, a 5.15% decrease, with the full-year FY2025 number at 0.81, down 5.15% from a year prior.
  • Equity Ratio hit 0.81 in Q4 2025 for Castle Biosciences, down from 0.83 in the prior quarter.
  • Over the last five years, Equity Ratio for CSTL hit a ceiling of 0.96 in Q1 2021 and a floor of 0.81 in Q4 2025.
  • Historically, Equity Ratio has averaged 0.89 across 5 years, with a median of 0.89 in 2021.
  • Biggest five-year swings in Equity Ratio: skyrocketed 30.9% in 2021 and later decreased 6.6% in 2022.
  • Tracing CSTL's Equity Ratio over 5 years: stood at 0.89 in 2021, then increased by 0.25% to 0.89 in 2022, then dropped by 3.27% to 0.86 in 2023, then dropped by 0.58% to 0.86 in 2024, then dropped by 5.15% to 0.81 in 2025.
  • Business Quant data shows Equity Ratio for CSTL at 0.81 in Q4 2025, 0.83 in Q3 2025, and 0.84 in Q2 2025.